NCT01023230View on ClinicalTrials.gov

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Hepatitis B, Chronic
Interventions
DRUG

DV-601

Six injections of DV-601 administered over a period of 12 weeks.

DRUG

Entecavir

Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.

Trial Locations (4)

85-030

Collegium Medicum Uniwersytet im. Mikołaja Kopernika, Bydgoszcz

71-455

Samodzielny Publiczny Wojewódzki Szpital Zespolony, Szczecin

01-201

Wojewódzki Szpital Zakaźny, Warsaw

50-349

NZOZ Centrum Badan Klinicznych, Wroclaw

Sponsors
All Listed Sponsors
lead

Dynavax Technologies Corporation

INDUSTRY